

Title Page

Title

Beyond hormone replacement: Quality of life in women with congenital hypogonadotropic hypogonadism

Author names and affiliations

Shota Dzemaili, PhD¹

Jitske Tiemensma, PhD²

Richard Quinton, MD³

Nelly Pitteloud, MD⁴

Diane Morin, PhD^{1, 5}

Andrew A. Dwyer, PhD, FNP-BC^{1, 4}

1. University of Lausanne, Institute of Higher Education and Research in Healthcare, Biopôle 2, Route de la Corniche 10, Lausanne, 1010, Switzerland

2. University of California Merced, Psychological Science, 5200 North Lake Road, Merced, CA 95343, USA

3. Department of Endocrinology, Institute for Human Genetics, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne NE1 3BZ, United Kingdom

4. Endocrinology, Diabetes & Metabolism Service of the Centre Hospitalier Universitaire Vaudois, 46 Rue du Bugnon, Lausanne, 1011

5. Laval University, Faculty of Nursing Science, 1050, Avenue de la Médecine, Québec City, Québec G1V 0A6

Corresponding author

Andrew A. Dwyer, PhD, FNP-BC
Boston College, William F. Connell School of Nursing
Maloney Hall, 140 Commonwealth Avenue
Chestnut Hill, MA 02467
Phone: 617-552-4250
E-mail : adwyer989@gmail.com

Short title

Beyond hormone replacement: women with CHH

Key words female infertility, illness perceptions, Kallmann syndrome, medication adherence, patient centered care, rare diseases

Text: 3318 words

Figures & Tables: 1 figure, 3 tables

Abstract

Objective Little is known about how women with isolated GnRH deficiency cope with their condition. This study aimed to examine the health and informational needs of women with congenital hypogonadotropic hypogonadism (CHH) and evaluate if their experiences differ from women with more common forms of infertility.

Design Cross-sectional, multiple methods study using web-based data collection to reach dispersed rare disease patients.

Methods A community-based participatory research framework was employed to develop an online survey and collect quantitative and qualitative data. Adult women diagnosed with CHH who had received at least one year of hormonal treatment completed the Morisky Medication Adherence Scale, Revised Illness Perception Questionnaire and Zung Self-Rating Depression Scale. Information on healthcare experiences, treatment outcomes and patient-reported challenges were also collected.

Results Women (n=55) were often diagnosed late (20.7 ± 7.4 , range: 10-48 years) and 16/20 patients receiving fertility treatment conceived. Poor adherence was frequently observed (34/55) while more than half (27/49) reported a gap in treatment exceeding a year. Low adherence correlated with depressive symptoms ($r=0.3$, $p>0.05$). Negative illness perceptions were pervasive and 30/55 exhibited some depressive symptoms - significantly greater than women with common female factor infertility ($p<0.01$). Symptoms were underappreciated by providers as only 15 of 55 patients had discussions about psychological services. Women identified isolation, need for information and finding expert care as challenges to living with CHH.

Conclusions Despite being a treatable form of female infertility, the presumable availability of treatment does not necessarily ensure adequate quality of life for women with isolated GnRH deficiency.

Introduction

Infertility affects ~10-15% of women globally, and is a significant health concern ¹. Sometimes referred to as the pilot light of reproduction, gonadotropin-releasing hormone (GnRH) secretion is essential for developing and maintaining reproductive capacity ². Acquired GnRH deficiency (i.e. hypothalamic amenorrhea) is a common cause of secondary amenorrhea that is reversible ³. More severe forms of GnRH deficiency, such as congenital hypogonadotropic hypogonadism (CHH), are much less common. However, CHH is responsive to hormonal therapy and is a treatable form of infertility that does not necessarily require invasive assisted reproduction techniques ⁴.

In its most severe form, CHH presents as a complete absence of puberty with undetectable serum gonadotropins and hypogonadal sex steroid levels. Clinical presentation is variable: some patients display partial puberty ⁵, there is a wide range of associated phenotypes (e.g. absent sense of smell, skeletal anomalies, mirror movements, renal agenesis) and cases of reversal have been reported ⁶. Similarly, genetic etiology is heterogeneous with more than 25 genes having been identified in relation to CHH and the genetic architecture can sometimes be complex as evidenced by oligogenicity ⁴. CHH is rare (1:4,000-10,000) and there is a striking sexual discordance. Combining three large patient cohorts from the United States (n=250) ⁷, United Kingdom (n=215) ⁸ and France (n=334) ⁹ reveals the male to female ratio to be 3.6 to 1. Yet, unlike many other rare disorders, effective treatments are available. Hormone replacement in the form of low dose oestradiol (titrated over time) is the standard treatment for younger

hypogonadal women to induce secondary sexual characteristics and menses ⁴. Combined gonadotrophin therapy or physiologic treatment with pulsatile GnRH are equally effective for inducing fertility in the vast majority of cases ¹⁰.

Compared to fertile counterparts, women with infertility have higher levels of stress, anxiety, and depression all of which can erode quality of life ¹¹. However, little is known about the experiences of women with CHH and how they cope with their condition. There is a body of literature on quality of life issues in women with primary infertility (i.e. Turner syndrome, TS) ¹². However, differences in terms of timing of diagnosis, phenotype, and fertility potential preclude extending findings from women with a hypogonadotrophic cause of infertility (TS) to those with a hypogonadotrophic etiology (CHH). Notably, conducting research in rare disease patients is challenged by the fact that these patients are dispersed and difficult to reach. Therefore, the purpose of this study was to partner with patients and use web-based data collection to reach women with CHH to conduct a needs assessment to identify targets for developing more patient-centered approaches to care for these endocrine patients.

Subjects and methods

Design and subjects

This cross-sectional needs assessment employed multiple methods within a community-based participatory research framework ¹³. We engaged patient community leaders in developing content and validating the online survey as well as for recruitment. Patients were identified via patient-oriented social media sites (i.e. Facebook, Rareconnect.org) and the international network studying GnRH deficiency (COST Action BM1105, www.gnrhdeficiency.eu) over a 14-month period (October 2014-December 2015). CHH was defined as previously reported ⁵ and diagnosis was confirmed in a 40% random sample of respondents as described ¹⁴. Adult women (18+ years) with CHH who had been on hormonal treatment for at least one year were included

in the analysis. The project was reviewed and approved by the local ethics committee and all participants provided opt-in electronic consent.

Needs assessment survey

We co-constructed an online survey with patients including items on patient demographics, health literacy ¹⁵, medical history, healthcare interactions, sexuality, as well as several validated questionnaires. The selection of questionnaires was based on their relevance, validity and widespread use that facilitates comparison with particular patient populations of interest (i.e. women with infertility, and men with CHH and patients with rare endocrine disorders and chronic conditions). The Morisky Medication Adherence Scale (MMAS) is an 8-item instrument that assesses medication taking behavior to determine low, medium or high adherence ¹⁶⁻¹⁸. The Zung Self-Rating Depression Scale (SDS) is a widely-used, validated 20-item instrument quantifying the severity of affective, somatic, psychomotor, and psychological depressive symptoms ^{19,20}. The Illness Perception Questionnaire - Revised (IPQ-R) includes 38 statements to assess emotional and cognitive representations of illness spanning 7 dimensions: *timeline acute/chronic* (beliefs about the chronic nature of the condition), *timeline cyclical* (beliefs regarding the cyclical nature of the condition), *consequences* (negative consequences of the disease), *personal control* (perceived personal controllability of the disease), *treatment control* (perceived treatment controllability of the disease), *emotional representations* (the emotional responses generated by the illness), and *illness coherence* (personal understanding of the disease) ²¹. Additionally, patients had the opportunity to provide a free text response identifying what they perceive to be the most challenging aspects of living with CHH.

Reference populations

To provide context for the depressive symptoms in women with CHH, SDS scores were compared to: a) men with CHH (n=101) ²², b) women seeking assisted fertility treatment (n=872)

¹¹ and c) community based rates in a healthy, non-psychiatric population (n=292) who completed the SDS monthly over the course of one full year ²³. Because there are no normative scores for the IPQ-R for the general population (i.e. healthy adults), comparisons were made to patients with acute or chronic pain ²⁴, men with CHH ²², and patients with acromegaly ²⁴ to provide a clinical context for these data. Age at CHH diagnosis was compared to a population-based sample for age of menarche ²⁵.

Analysis

Descriptive statistics were used to present survey data. Comparisons between groups were performed using Student's t-test or Mann-Whitney rank sum test as appropriate. Categorical values were compared using Chi-square test while Pearson product-moment correlations were performed to assess the associations between survey data. IPQ-R subscales were compared across the CHH and reference groups using ANOVA with Bonferroni post-hoc correction for multiple comparisons. Z-Scores were used to assess differences in the proportion of patients exhibiting depressive symptoms compared to community base rates. Survey data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL). All data are presented as mean \pm SD unless otherwise noted and a $p \leq 0.05$ was considered statistically significant. Open-ended responses were analyzed using NVivo11 (QSR International PSY Ltd., Melbourne Australia). Deductive thematic analysis (deductive coding) was conducted by two independent investigators (SD:AD). Meaningful units were coded. These codes were sorted into categories and themes in an iterative process and consensus was achieved by discussion. The most frequent themes were given particular emphasis ²⁶.

Results

The web-based survey was online for 14-months during which time 68 women responded. After removing incomplete survey responses and those not meeting inclusion criteria, 55 surveys

were included for analysis. Given the rarity of women with CHH ⁷⁻⁹, it appears that the combination of community partnerships and social media recruitment were effective for reaching these dispersed patients ¹⁴. Patient sociodemographic characteristics are depicted in **Table 1**. The women ranged in age from 18-68 years (mean 35±10, median 34), were well-educated (44/55, university or higher) with adequate health literacy and the majority of women were employed (41/55).

Given that menarche is an important single-event signpost of puberty and that 90% of CHH women present with primary amenorrhea ⁵, earlier diagnosis and treated would be expected compared to male counterparts who lack such a hallmark. However, we found no such pattern (females: n=55; 95% CI: 18.7-22.7, males: n=101; 17.6-20.2 yrs; $p=0.16$) ²². The women were diagnosed between 10-48 years of age (**Figure 1A**), and more than half (n=32) had received any meaningful treatment prior to age 18 (95% CI: 17.2-20.6 yrs). Nearly two-thirds (34/55) of survey respondents had been seen at a specialized academic medical center (**Table 2**). Twenty women underwent fertility-inducing treatment, two-thirds (13/20) of whom at an academic medical center and the vast majority (16/20) successfully conceived, consistent with rates previously reported ^{27, 28}, and in line with male CHH counterparts (95% CI: 60-85%) ²⁹. In total, nearly half (25/55) of women had undergone genetic testing yet significantly fewer (11/55, $p<0.005$) received genetic counseling. Among surveyed patients, women receiving fertility-inducing treatment were not more likely to have genetic testing (12/20, $p=0.10$), or counseling (5/20, $p=0.48$) compared to the larger group.

All respondents included in the analysis had been on treatment for at least one year. Women completed the MMAS to assess adherence behavior (**Table 2**) and provided self-reported longest duration off treatment (**Fig 1B**). Notably, MMAS scores indicated low adherence in nearly two thirds (34/55) of women. Lifetime duration of treatment was weakly correlated with

MMAS ($r=0.29$, $p<0.05$). Only 11/49 reported never having a lapse in treatment – a proportion similar to those exhibiting the highest level of adherence on the MMAS (**Table 1**). However, more than half (27/49) reported long gaps in treatment (i.e. 12 months or longer). Similarly, 18/43 claimed to have gone 2 years or longer without seeing a healthcare provider (data not shown).

Across IPQ-R dimensions, women and men had comparable perceptions of their CHH with scores indicating significant emotional impact and negative consequences²² (**Table 3**). These findings extend the findings of a small qualitative study including interviews with 5 women with CHH³⁰. Women with CHH perceived more negative consequences of their illness compared to both patients with acute pain and patients with acromegaly (both $p<0.01$) yet less than patients with chronic pain. The negative emotional impact of CHH was larger than in patients with acromegaly ($p<0.01$) but not different from patients with acute or chronic pain. Both negative consequences and emotional impact were modestly correlated with poorer medication adherence ($r=0.298$ and $r=0.33$ respectively, both $p<0.05$). Furthermore, females with CHH perceived less personal control over their illness than patients with acute pain ($p<0.01$), but did not differ from patients with chronic pain or acromegaly. In terms of treatment control, females with CHH perceived less treatment control than patients with acute pain or acromegaly (both $p<0.01$), but more treatment control than patients with chronic pain ($p=0.01$). Lastly, women with CHH exhibited the highest score on illness coherence compared to patients with acute or chronic pain (both $p<0.01$). This better understanding of their illness could be related to the congenital nature of CHH.

More than half of women (30/55) exhibited some depressive symptoms. This is significantly increased compared to the 9% observed in a community dwelling non-psychiatric population ($p<0.001$)²³ yet similar to their male CHH counterparts (64/100, $p=N.S.$)²². Compared to those

presenting with more common female infertility (14.7% of 872 women)¹¹, women with CHH were more likely to exhibit depressive symptoms ($p<0.01$) and this relationship persisted when we limited the analysis to only those patients (25.6% of 193 women) with female factor infertility ($p<0.01$). In total, 14/55 of women with CHH exhibited mild depressive symptoms, 9/55 had moderated symptoms similar to the type of depression treated in an ambulatory setting while 7/55 had severe depressive symptoms akin to major depressive disorder. We found depressive symptoms were moderately correlated with poorer medication adherence ($r=0.3$, $p<0.05$) consistent with prior studies in patients with chronic diseases³¹. Depressive symptoms were also correlated with illness perception dimensions. We observed a strong correlation between depressive symptoms and negative emotional impact of CHH ($r=0.6$, $p<0.0001$), a moderate relationship with consequences ($r=0.42$, $p<0.01$) and a weak association with illness coherence – how one makes sense of their condition ($r=0.35$, $p<0.01$).

Importantly, the increased depressive symptoms appear to be underappreciated as only 15 women stated that their provider had discussed or provided a referral for psychological counseling. Half of the patients (28/55) perceived that their healthcare provider well-understood the medical aspects of their GnRH deficiency yet significantly fewer felt that their provider understood how patients feel about living with CHH (14/55, $p<0.01$). Women with CHH were more likely than their male counterparts to have been in a relationship and sexually active (both, $p<0.05$)³². Despite this, nearly all women (51/55) cited issues of body image concerns, with (44/55) reporting feelings of shame or embarrassment about their body, and over half (32/55) found intimate relationships difficult and had experienced teasing or ridicule about their lack of development (31/55).

Qualitative data were also collected as part of the survey. Patients were asked to describe the most challenging aspect of living with CHH and approximately two-thirds (36/55) responded.

Responses were coded and the 61 topics thematically clustered in three categories: i) isolation and insecurity (n=24), ii) need for information and support (n=24), and iii) delayed diagnosis and finding expert care (n=13). A table with representative quotes is provided in the online supplemental data. We also asked patients where they sought information about their condition. Nearly all women (52/55) reported that they found information about their condition on the internet, 46/55 via online community and social media (i.e. Facebook, Rareconnect.org), and 44/55 were informed by healthcare professionals. Despite high education and health literacy levels, approximately half (27/55) sought information from the medical literature. Patients rated healthcare professionals as the most important source of information followed by online community and the internet. Ratings of importance were not statistically significant between these sources ($p=0.13$).

Discussion

We found that women with CHH are often diagnosed late and experience significant physical, social and psychological consequences in relation to their condition. These findings have implications for developing more patient-centered approaches to care for these women. This cross-sectional study of 55 women is perhaps the most robust portrayal of this patient population to date. Data on women with CHH are scant with only a handful of single-center studies reporting on very small samples (i.e. $n<15$). Additionally, patients were involved in developing the study - this strengthens our confidence that the identified targets for improving care are aspects that matter to patients.

Some aspects of this study may limit the ultimate transferability of the findings to all women with CHH. First, these patients were well-educated with high levels of health literacy. Second, the inherent Anglophone bias should engender caution in considering cultural equivalence. Third, given the sample size, we may be underpowered in some of our analyses. Indeed, difficulty in

recruiting adequate numbers of patients with rare diseases is widely acknowledged. This challenge informed our strategy of using the internet and patient-oriented social media to reach these dispersed patients, which we acknowledge as a potential source of sampling bias. Finally, self-report nature of the instruments employed has its own limitations, albeit our goal was to better understand patient perspectives to identify unmet needs as an initial step in developing more patient-centered approaches to care.

Data on the age of diagnosis in CHH women comprises a single article (n=5; mean: 23±9, range: 12-35, median 21 yrs)³⁰ along with some unpublished historic data (females: n=38; mean: 18.2±5, range: 10-53 yrs)³³. We found women with CHH are often diagnosed quite late and only 58% had received treatment prior to age 18. It is well-established that later induction of puberty for adolescent girls with Turner syndrome (TS) is associated with poor self-esteem, difficult social adjustment and diminished sex life^{34, 35}. Further, late diagnosis (and initiation of treatment) negatively impacts psychosexual development in men with CHH³². Thus, greater attention to earlier detection and timely initiation of sex steroid therapy seems warranted.

The vast majority (16 of 20) of women who underwent fertility treatment were able to conceive, in line with published literature^{27, 28}. Notably, relatively few (11/55) women had received genetic counseling. This is surprising given that the American College of Medical Genetics considers abnormal pubertal timing a clinical presentation requiring referral to a medical genetics professional (i.e. genetic counselor)³⁶. Further, both the European Society of Human Genetics and the European Society of Human Reproduction and Embryology consider genetic counseling necessary when genetic factors are related to the cause of infertility³⁷. However, in our cohort, women receiving fertility-inducing treatment were no more likely to have genetic testing or counseling. These data suggest either lack of awareness of the importance of genetic counseling for these patients, or may reflect inadequate access to specialists with sufficient

understanding of the sometimes complex genetics of CHH ³⁸. Improved access to genetic counseling appears to be a relevant target for enhancing patient care.

Long term adherence to treatment was problematic as more than half of women had a gap in care of a year or longer. Without treatment, these women rapidly become hypogonadal, with deleterious impact on mood, well-being, sex life, and bone health. A Finnish cohort of 24 men and 9 women found patients with the longest gaps in treatment exhibited the most impaired bone density ³⁹. Additionally, risk for osteopenia/osteoporosis may be further compounded by late diagnosis, as up to 90% of adult bone mass is accumulated during adolescence ⁴⁰. Delays in diagnosis (and treatment initiation) could prolong estrogen deficiency thus impairing bone mineralization. These data highlight the importance of adequate hormone replacement and ongoing follow-up to monitor bone density and adherence as well as the role for a coordinated transition to adult services to facilitate continuity of care ^{4, 39, 41}.

Women had negative illness perceptions yet exhibited relatively high scores on illness coherence. Interestingly, CHH women who had received fertility treatment (and were able to conceive) had significantly lower ratings of negative consequences ($p<0.05$) and emotional impact ($p<0.05$) compared to those without children. While the sample is small, this may represent a psychological buffering effect of successful fertility treatment. We did not employ a formal health-related quality of life (HR-QoL) instrument in this study, yet the negative illness perceptions and increased depressive symptoms observed in women with CHH are consistent with impaired HR-QoL. A recent study of women with TS showed impaired HR-QoL compared to controls ³⁵. Interestingly, the study included 21 women with other types of congenital hypogonadism (14 with CHH, 7 with 46XX gonadal dysgenesis) whose SF-36 scores were quite similar. A subset of these patients completed the Female Sexual Function Index revealing impaired sexual desire, arousal, lubrication, orgasm and global satisfaction compared to

controls ³⁵. Similarly in our cohort, body image concerns were pervasive and the majority of women stated that intimate relationships were difficult. A recent study of young adults with CHH during transition found that few young women felt adequately informed about sexuality (2/7), intimate relationships (1/7), potential future fertility (1/7) or intercourse/potential discomfort with sex (0/7) ⁴². These current data underscore the need for appropriate anticipatory guidance on the topics of sexuality and intimate relationships.

The qualitative data analysis suggests that women struggle with feelings of isolation and finding expert care. They frequently reported having used the internet and social media to learn about their condition and to find support from other patients ¹⁴. The Pew Foundation identified patients with a rare disease as 'internet power-users' ⁴³, which aligns with our findings. We have previously shown that web-based modalities are used by and acceptable to patients with CHH ¹⁴. This may present a novel avenue for reaching these dispersed patients, engaging them and promoting health and self-management. The Institute of Medicine defines patient-centered care as being guided by patient values and is both respectful of, and responsive to individual preferences, needs, and values ⁴⁴. The Picker Principles of patient-centered care ⁴⁵ provide a useful framework for developing more patient-centered approaches to care. Accordingly, we have charted the findings from the present study onto this framework along with suggested avenues for translating the results of this study into improved care for women with CHH (see supplementary file).

In summary, this participatory, multiple methods needs assessment identifies that women with CHH frequently have lengthy gaps in treatment/care, perceive their condition to have a significant psychosocial impact on their life, and exhibit increased depressive symptoms. Care for these women could be improved by earlier diagnosis and timely initiation of treatment, greater access to genetic counseling, and providing accurate information about CHH (and

fertility treatment) as well as offering professional and peer-to-peer psychological support. The internet is effective for reaching and connecting dispersed patients and web-based platforms may hold promise for delivering patient-centered interventions to empower patients for improved self-management and adherence.

Declaration of interests

The authors have no competing interests to declare.

Funding

No specific funding was obtained for this study.

Author contributions

AAD, RQ, NP, and DM conceived and designed the study. AAD collected the data. SD, JT, and AAD analyzed the data and drafted the manuscript. RQ, NP, and DM critically revised the manuscript. All authors approved the final manuscript version.

Acknowledgements

We wish to thank the patients for their generous participation and acknowledge Mr. Neil Smith and the other patient community leaders who contributed to this work. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, 294 Lindura Ct., Las Vegas, NV 89138-4632. This project was registered at www.clinicaltrials.gov (NCT01914172).

11. References

1. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S & Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. *PLoS Med* 2012 **9** e1001356.
2. Balasubramanian R & Crowley WF, Jr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. *Mol Cell Endocrinol* 2011 **346** 4-12.
3. Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, Hughes VA, Seminara SB, Boepple PA, Sidis Y, Crowley WF, Jr., Martin KA, Hall JE & Pitteloud N. A genetic basis for functional hypothalamic amenorrhea. *N Engl J Med* 2011 **364** 215-225.
4. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dode C, Dunkel L, Dwyer AA, Giacobini P, Hardelin JP, Juul A, Maghnie M, Pitteloud N, Prevot V, Raivio T, Tena-Sempere M, Quinton R & Young J. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. *Nat Rev Endocrinol* 2015 **11** 547-564.
5. Shaw ND, Seminara SB, Welt CK, Au MG, Plummer L, Hughes VA, Dwyer AA, Martin KA, Quinton R, Mericq V, Merino PM, Gusella JF, Crowley WF, Jr., Pitteloud N & Hall JE. Expanding the phenotype and genotype of female GnRH deficiency. *J Clin Endocrinol Metab* 2011 **96** E566-576.
6. Dwyer AA, Raivio T & Pitteloud N. MANAGEMENT OF ENDOCRINE DISEASE: Reversible hypogonadotropic hypogonadism. *Eur J Endocrinol* 2016 **174** R267-274.
7. Seminara SB, Hayes FJ & Crowley WF, Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. *Endocrine reviews* 1998 **19** 521-539.
8. Quinton R, Duke VM, Robertson A, Kirk JM, Matfin G, de Zoysa PA, Azcona C, MacColl GS, Jacobs HS, Conway GS, Besser M, Stanhope RG & Bouloux PM. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. *Clin Endocrinol (Oxf)* 2001 **55** 163-174.
9. Bry-Gaillard H, Trabado S, Bouligand J, Sarfati J, Francou B, Salenave S, Chanson P, Brailly-Tabard S, Guiochon-Mantel A & Young J. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics. *Ann Endocrinol (Paris)* 2010 **71** 158-162.
10. Martin KA, Hall JE, Adams JM & Crowley WF, Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. *J Clin Endocrinol Metab* 1993 **77** 125-129.
11. Chiaffarino F, Baldini MP, Scarduelli C, Bommarito F, Ambrosio S, D'Orsi C, Torretta R, Bonizzoni M & Ragni G. Prevalence and incidence of depressive and anxious symptoms in couples undergoing assisted reproductive treatment in an Italian infertility department. *Eur J Obstet Gynecol Reprod Biol* 2011 **158** 235-241.
12. Garrido Oyarzun MF & Castelo-Branco C. Sexuality and quality of life in congenital hypogonadisms. *Gynecol Endocrinol* 2016 **32** 947-950.
13. Wallerstein N & Duran B. Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity. *Am J Public Health* 2010 **100 Suppl 1** S40-46.
14. Dwyer AA, Quinton R, Morin D & Pitteloud N. Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for online interventions and peer-to-peer support. *Orphanet J Rare Dis* 2014 **9** 83.

15. Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, Bradley KA, Nugent SM, Baines AD & Vanryn M. Validation of screening questions for limited health literacy in a large VA outpatient population. *J Gen Intern Med* 2008 **23** 561-566.
16. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE & Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. *Am J Manag Care* 2009 **15** 59-66.
17. Morisky DE & DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. *J Clin Epidemiol* 2011 **64** 255-257; discussion 258-263.
18. Morisky DE, Ang A, Krousel-Wood M & Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. *J Clin Hypertens (Greenwich)* 2008 **10** 348-354.
19. Zung WW. A Self-Rating Depression Scale. *Archives of general psychiatry* 1965 **12** 63-70.
20. Zung WW. The role of rating scales in the identification and management of the depressed patient in the primary care setting. *J Clin Psychiatry* 1990 **51 Suppl** 72-76.
21. Moss-Morris RW, J.; Petrie, K.J.; Horne, R.; CAmeron, L.D.; Buick, D. The revised illness perception questionnaire (IPQ-R). *Psychology and Health* 2002 **17** 1-16.
22. Dwyer AA, Tiemensma J, Quinton R, Pitteloud N & Morin D. Adherence to treatment in men with hypogonadotropic hypogonadism. *Clin Endocrinol (Oxf)* 2016.
23. Barrett J, Hurst MW, DiScala C & Rose RM. Prevalence of depression over a 12-month period in a nonpatient population. *Archives of general psychiatry* 1978 **35** 741-744.
24. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA & Biermasz NR. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. *The Journal of clinical endocrinology and metabolism* 2011 **96** 3550-3558.
25. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG & Hasemeier CM. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. *Pediatrics* 1997 **99** 505-512.
26. Saldana J. *Coding Manual for Qualitative Researchers*. Thousand Oaks, CA: Sage, 2009.
27. Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L, Arnone R, Sambataro M & Falbo A. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. *J Clin Endocrinol Metab* 1994 **79** 1215-1220.
28. Gronier H, Peigne M, Catteau-Jonard S, Dewailly D & Robin G. [Ovulation induction by pulsatile GnRH therapy in 2014: literature review and synthesis of current practice]. *Gynecol Obstet Fertil* 2014 **42** 732-740.
29. Rastrelli G, Corona G, Mannucci E & Maggi M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. *Andrology* 2014 **2** 794-808.
30. Hofmann J, Watzlawik M & Richter-Appelt H. Living with Kallmann Syndrome - Analysis of Subjective Experience Reports from Women. *Geburtshilfe Frauenheilkd* 2013 **73** 1112-1120.
31. DiMatteo MR, Lepper HS & Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000 **160** 2101-2107.
32. Dwyer AA, Quinton R, Pitteloud N & Morin D. Psychosexual development in men with congenital hypogonadotropic hypogonadism on long-term treatment: a mixed methods study. *Sex Med* 2015 **3** 32-41.
33. Quinton R. Phenotypic aspects of Kallmann syndrome. University of Cambridge, 2001.
34. Carel JC, Elie C, Ecosse E, Tauber M, Leger J, Cabrol S, Nicolino M, Brauner R, Chaussain JL & Coste J. Self-esteem and social adjustment in young women with Turner syndrome--influence of pubertal management and sexuality: population-based cohort study. *J Clin Endocrinol Metab* 2006 **91** 2972-2979.

35. Ros C, Alobid I, Balasch J, Mullol J & Castelo-Branco C. Turner's syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. *Am J Obstet Gynecol* 2013 **208** 484 e481-486.
36. Pletcher BA, Toriello HV, Noblin SJ, Seaver LH, Driscoll DA, Bennett RL & Gross SJ. Indications for genetic referral: a guide for healthcare providers. *Genet Med* 2007 **9** 385-389.
37. Harper J, Geraedts J, Borry P, Cornel MC, Dondorp WJ, Gianaroli L, Harton G, Milachich T, Kaariainen H, Liebaers I, Morris M, Sequeiros J, Sermon K, Shenfield F, Skirton H, Soini S, Spits C, Veiga A, Vermeesch JR, Viville S, de Wert G, Macek M, Jr., Eshg E & EuroGentest. Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. *Hum Reprod* 2014 **29** 1603-1609.
38. Au MG, Crowley WF, Jr. & Buck CL. Genetic counseling for isolated GnRH deficiency. *Mol Cell Endocrinol* 2011 **346** 102-109.
39. Laitinen EM, Hero M, Vaaralahti K, Tommiska J & Raivio T. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. *Int J Androl* 2012 **35** 534-540.
40. Divasta AD & Gordon CM. Hormone replacement therapy and the adolescent. *Curr Opin Obstet Gynecol* 2010 **22** 363-368.
41. Dwyer AA, Phan-Hug F, Hauschild M, Elowe-Gruau E & Pitteloud N. TRANSITION IN ENDOCRINOLOGY: Hypogonadism in Adolescence. *Eur J Endocrinol* 2015.
42. Godbout A, Tejedor I, Malivoir S, Polak M & Touraine P. Transition from pediatric to adult healthcare: assessment of specific needs of patients with chronic endocrine conditions. *Horm Res Paediatr* 2012 **78** 247-255.
43. Fox S. Peer-to-peer healthcare: Many people - especially those living with chronic or rare diseases - use online connections to supplement professional medical advice. In *Pew Internet and Americal Life Project* p26. Washington, D.C: Pew Research Center, 2011.
44. (U.S.) IoM. Crossing the quality chasm: a new health system for the 21st century. Washington, D.C., 2001.
45. Frampton S, Guastello, S., Brady, C., Hale, M., Horowitz, S., Bennett-Smith, S., Stone, S. *Picker Institute Patient-Centered Care Improvement Guide*. Derby, CT Planetree, Inc., 2008.

Figure Legends

Figure 1. Age at CHH diagnosis and self-reported adherence to treatment. (A) Age at CHH diagnosis for 55 women ranged from 10-48 years. The mean age at menarche for Caucasian females is shown as a horizontal line and the shaded region depicts \pm two standard deviations³⁶. Only 11/55 of women were diagnosed by age 15. (B) Self-reported adherence to treatment (n=49). Approximately one-quarter of respondents reported never having a gap in treatment. In total, more than half (27/49) reported a gap in treatment of a year or longer. Similarly 20/46 women reported having a lapse in healthcare exceeding one year (data not shown). Age at diagnosis was moderately correlated with duration of gap in healthcare ($r=0.56$, $p<0.001$).

Figure 1. Age at CHH diagnosis and self-reported adherence to treatment




Table 1. Sociodemographic information of women with CHH (n=55)

Age (years)	n (%)
18-29	16 (29%)
30-39	25 (46%)
40-49	9 (16%)
50-59	4 (7%)
60+	1 (2%)
Education	
high school/vocational	10 (18%)
university	28 (51%)
post-graduate	16 (29%)
no response	1 (2%)
Health literacy²⁵	
adequate literacy	45/55 (82%)
inadequate literacy	10/55 (18%)
Employment	
working full-time	32 (58%)
working part-time	9 (16%)
not working/unemployed	8 (15%)
retired	1 (2%)
student	5 (9%)
Relationship status	
married	21 (38%)
in a relationship	14 (25%)
single	9 (16%)
never been in a relationship	4 (7%)
divorced	7 (13%)

Table 2. Healthcare experiences of women with CHH (n=55)

Medical history		n (%)
seen at a specialized academic medical center		34 (62%)
genetic testing performed		25 (45%)
genetic counseling received		11 (20%)
sought psychological counseling		16 (29%)
Healthcare interactions		
provider understands medical aspects of CHH		28 (51%)
provider understands patient's feelings of living with CHH		14 (25%)
provider discussed or gave referral for counseling		15 (27%)
experienced discrimination in the healthcare system		15 (27%)
Treatment and adherence		
duration of treatment: mean±SD (range, median)		16 ±10 yrs (1-42, 17)
MMAS low adherence		34 (62%)
medium adherence		12 (22%)
high adherence		9 (16%)
Fertility outcomes		
received fertility inducing treatment		20/55 (36%)
biologic children		16/20 (80%)

Use of
the

©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, 294 Lindura Ct., Las Vegas, NV 89138-4632.

Table 3. Comparison of IPQ-R scores between female CHH patients and other patient groups

IPQ-R	CHH (women) n=55	CHH (men) n=101	acute pain n=35	chronic pain n=63	acromegaly n=81
Timeline (acute/chronic)	27.2 (3.6)	26.7 (3)	13.4 (5)**	23.1 (4)**	22.9 (6)**
Timeline (cyclical)	9.2 (3.9)	9.7 (4)	9.4 (3)	12.9 (4)**	10.1 (4)
Consequences	20.0 (5.1)	21.3 (4)	14.2 (4)**	23.5 (4)**	16.9 (5)**
Emotional representations	17.8 (6.2)	19.2 (6)	16.1 (4)	19.8 (4)	12.6 (4)**
Personal control	19.6 (4.9)	19.9 (5)	22.9 (4)**	18.4 (4)	17.5 (5)
Treatment control	16.1 (3.3)	15.5 (4)	19.4 (3)**	14.2 (3)*	18.1 (3)**
Illness coherence	16.5 (4.7)	18.1 (4)	9.3 (3)**	13.4 (5)**	17.5 (3)

Data are mean (SD), * p<0.05 compared with CHH (women), ** p<0.01 compared with CHH (women)